JO3149B1 - تراكيب وطرق إستعمال للأجسام المضادة العلاجية - Google Patents

تراكيب وطرق إستعمال للأجسام المضادة العلاجية

Info

Publication number
JO3149B1
JO3149B1 JOP/2009/0267A JOP20090267A JO3149B1 JO 3149 B1 JO3149 B1 JO 3149B1 JO P20090267 A JOP20090267 A JO P20090267A JO 3149 B1 JO3149 B1 JO 3149B1
Authority
JO
Jordan
Prior art keywords
compositions
methods
antibodies
therapeutic antibodies
baffr
Prior art date
Application number
JOP/2009/0267A
Other languages
English (en)
Inventor
Schaadt Eveline
Neugebauer Julia
Urlinger Stefanie
Heusser Christoph
Woisetschlaeger Maximilian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3149(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3149B1 publication Critical patent/JO3149B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

يتعلق الإختراع الحالي بالأجسام المضادة التي ترتبط بشكل محدد إلى مستقبل BAFF (BAFFR). الإختراع يتعلق بشكل محدد بأجسام مضادة محددة حيث ضواد BAFFR هى نشاط يستنفذ خلية B داخل الجسم وتراكيب وطرق إستعمال للأجسام المضادة المذكورة لمعالجة الاضطرابات الباثولوجية التي يمكن أن تعالج بقتل أو إستنفاذ خلايا B، مثل داء الذئبة الشامل الحامومى أو إلتهاب مفاصل روماتزمي أو أمراض ذاتية المناعة أخرى أو ورم غدد لمفاوية ، لوكيميا وورم نقيي myelomas.
JOP/2009/0267A 2008-07-17 2009-07-16 تراكيب وطرق إستعمال للأجسام المضادة العلاجية JO3149B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15

Publications (1)

Publication Number Publication Date
JO3149B1 true JO3149B1 (ar) 2017-09-20

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2009/0267A JO3149B1 (ar) 2008-07-17 2009-07-16 تراكيب وطرق إستعمال للأجسام المضادة العلاجية

Country Status (40)

Country Link
US (3) US8106163B2 (ar)
EP (1) EP2315780B8 (ar)
JP (2) JP5767109B2 (ar)
KR (2) KR101314369B1 (ar)
CN (1) CN102119174B (ar)
AR (1) AR072749A1 (ar)
AU (1) AU2009272771B2 (ar)
BR (1) BRPI0915928B8 (ar)
CA (1) CA2730063C (ar)
CL (1) CL2011000086A1 (ar)
CR (1) CR11863A (ar)
CU (1) CU23878B1 (ar)
CY (1) CY1116800T1 (ar)
DK (1) DK2315780T3 (ar)
DO (1) DOP2011000016A (ar)
EA (1) EA024492B1 (ar)
EC (1) ECSP11010761A (ar)
ES (1) ES2547270T3 (ar)
GE (1) GEP20146129B (ar)
HR (1) HRP20151227T1 (ar)
HU (1) HUE025778T2 (ar)
IL (1) IL210485A (ar)
JO (1) JO3149B1 (ar)
MA (1) MA32481B1 (ar)
MX (1) MX2011000616A (ar)
MY (1) MY158980A (ar)
NI (1) NI201100017A (ar)
NZ (1) NZ590057A (ar)
PE (1) PE20110563A1 (ar)
PL (1) PL2315780T3 (ar)
PT (1) PT2315780E (ar)
RS (1) RS54299B1 (ar)
SG (1) SG193805A1 (ar)
SI (1) SI2315780T1 (ar)
SM (1) SMP201100010B (ar)
SV (1) SV2011003807A (ar)
TW (1) TWI508742B (ar)
UY (1) UY31987A (ar)
WO (1) WO2010007082A1 (ar)
ZA (1) ZA201008952B (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
PL3413894T3 (pl) 2016-02-10 2020-10-05 Novartis Ag Zastosowanie inhibitorów aktywności lub czynności PI3K do leczenia pierwotnego zespołu Sjögrena
CN116041514A (zh) * 2016-06-06 2023-05-02 希望之城 Baff-r抗体及其用途
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
CN110662768B (zh) * 2017-05-24 2024-01-30 Als治疗发展学会 治疗性抗cd40配体抗体
IL271194B2 (en) * 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
PL3823990T3 (pl) * 2018-07-20 2026-04-20 TeneoTwo, Inc. Przeciwciała łańcucha ciężkiego wiążące się z cd19
JPWO2020202839A1 (ar) * 2019-03-29 2020-10-08
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
JP2023501781A (ja) 2019-11-06 2023-01-19 ノバルティス アーゲー シェーグレン症候群の処置
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
US20230340136A1 (en) * 2020-08-04 2023-10-26 Novartis Ag Treatment of cll
IL300086A (en) 2020-08-04 2023-03-01 Novartis Ag Treatment of B-cell malignancies
CN118459585A (zh) * 2020-09-07 2024-08-09 白先宏 Baff-r结合分子及其应用
US20250215081A1 (en) * 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
US20240228644A1 (en) * 2021-05-04 2024-07-11 Novartis Ag Treatment for systemic lupus erythematosus using anti-baffr antibodies
JP2024517796A (ja) * 2021-05-04 2024-04-23 ノバルティス アーゲー 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2024537772A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｂａｆｆ－ｒを標的化する抗体及びその使用
JP2026510999A (ja) 2023-03-21 2026-04-10 バイオグラフ ５５，インク． Ｃｄ１９／ｃｄ３８多重特異性抗体
WO2025058962A1 (en) * 2023-09-11 2025-03-20 Absci Corporation High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria
WO2025131888A1 (en) 2023-12-19 2025-06-26 Basf Se Modified alkoxylated polyalkylene imines or modified alkoxylated polyamines
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75049C2 (uk) * 1999-08-17 2006-03-15 Байоджен Айдек Ма Інк. Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
BRPI0518994A2 (pt) * 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
SG193805A1 (en) 2013-10-30
EP2315780B1 (en) 2015-08-19
DK2315780T3 (en) 2015-10-19
EP2315780B8 (en) 2015-09-23
EA024492B1 (ru) 2016-09-30
IL210485A (en) 2015-03-31
PT2315780E (pt) 2015-11-30
CN102119174A (zh) 2011-07-06
KR101314369B1 (ko) 2013-10-10
US20120195913A1 (en) 2012-08-02
ES2547270T3 (es) 2015-10-05
MA32481B1 (ar) 2011-07-03
UY31987A (es) 2010-02-26
CN102119174B (zh) 2015-01-21
JP2011527896A (ja) 2011-11-10
AR072749A1 (es) 2010-09-15
NI201100017A (es) 2012-08-17
CR11863A (es) 2011-02-11
DOP2011000016A (es) 2011-02-15
JP6077587B2 (ja) 2017-02-08
WO2010007082A1 (en) 2010-01-21
CU23878B1 (es) 2013-04-19
CA2730063C (en) 2017-04-18
JP5767109B2 (ja) 2015-08-19
US9382326B2 (en) 2016-07-05
HUE025778T2 (en) 2016-05-30
KR101545795B1 (ko) 2015-08-19
ZA201008952B (en) 2012-01-25
AU2009272771B2 (en) 2012-09-20
EA201100191A1 (ru) 2011-08-30
SMP201100010B (it) 2011-09-09
HRP20151227T1 (hr) 2015-12-18
KR20110020914A (ko) 2011-03-03
US8106163B2 (en) 2012-01-31
AU2009272771A1 (en) 2010-01-21
SI2315780T1 (sl) 2015-11-30
JP2015133983A (ja) 2015-07-27
PE20110563A1 (es) 2011-08-29
CL2011000086A1 (es) 2011-07-01
TWI508742B (zh) 2015-11-21
RS54299B1 (sr) 2016-02-29
GEP20146129B (en) 2014-08-11
CU20110013A7 (es) 2012-06-21
SMAP201100010A (it) 2011-05-06
US20120183529A1 (en) 2012-07-19
TW201006493A (en) 2010-02-16
US9340620B2 (en) 2016-05-17
PL2315780T3 (pl) 2016-01-29
US20100021452A1 (en) 2010-01-28
BRPI0915928B8 (pt) 2021-05-25
SV2011003807A (es) 2011-03-23
CA2730063A1 (en) 2010-01-21
NZ590057A (en) 2012-08-31
ECSP11010761A (es) 2011-02-28
MY158980A (en) 2016-11-30
MX2011000616A (es) 2011-02-24
CY1116800T1 (el) 2017-03-15
KR20130098432A (ko) 2013-09-04
BRPI0915928A2 (pt) 2015-11-03
IL210485A0 (en) 2011-03-31
BRPI0915928B1 (pt) 2020-10-20
HK1150839A1 (en) 2012-01-13
EP2315780A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
JO3149B1 (ar) تراكيب وطرق إستعمال للأجسام المضادة العلاجية
EP2322557A3 (en) Compositions and methods for treating proliferative disorders
JOP20180019A1 (ar) بيرولات [3، 4-سي] اوكتاهيدروبيرولو ثنائية الاستبدال كمعدلات لمستقبل اوريكسين
MX380755B (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MX2011011338A (es) Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
PH12014502698B1 (en) Improved antagonist antibodies against gdf-8 and uses therefor
IN2012DN02735A (ar)
IN2012DN00754A (ar)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2013005549A (es) Aminas heterociclicas y sus usos.
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
IN2012DN06588A (ar)
TN2010000599A1 (en) Compositions and methods of use for therapeutic antiodies
CO6341571A2 (es) Composiciones y metodos de uso para anticuerpos terapeuticos
WO2009108635A3 (en) Novel compositions for treatment of diseases related to activated lymphocytes